



ABSTRACT

COVID-19 –Conduct of Sero-survey phase III using Quantitative Immuno Assay detecting IgG Antibodies against SARS CoV-2 Spike Protein in Tamil Nadu-
Permission – Granted – Orders - Issued.

MEDICAL AND FAMILY WELFARE (P1) DEPARTMENT

G.O.(D) No.840

Dated: 16.07.2021
Thiruvalluvar Aandu- 2052
Pilava, Aani – 32

1. G.O.(D)No.669, Health and Family Welfare (P1) Department, dated: 29.07.2020.
2. From the Director of Public Health and Preventive Medicine, Chennai letter No. 56135/LAB/2021, dated: 21.06.2021.

ORDER:

In Government Order first read above, Government have granted permission to conduct a Sero-survey with 24,000 sample size using CLIA method in Tamil Nadu.

2. In the letter second read above, the Director of Public Health and Preventive Medicine has stated that the Indian Council of Medical Research (ICMR) has advised the States to conduct Sero-survey to measure COVID-19 exposure in the population and the Department has already completed two phases of COVID-19 Sero-survey in Tamil Nadu, Phase I in Oct/Nov 2020 and Phase II in April 2021. The overall sero prevalence was 32% (Phase I) and 23% (Phase II, except Greater Chennai Corporation) in Tamil Nadu. In continuation of the Sero-survey conducted earlier, Phase III survey has been planned from 28th June 2021 onwards.

3. The Director of Public Health and Preventive Medicine has also stated that a total of 765 clusters covering a population of 22,950 in Tamil Nadu (except Greater Chennai Corporation) for Sero-survey Phase III has been planned from whom the blood samples will have to be collected and transported to the 6 designated Public Health Laboratories for testing and analysis by CLIA for the detection of SARS CoV-2 IgG antibodies. The Phase III survey will be conducted using a Quantitative Immuno Assay detecting IgG Antibodies against SARS CoV-2 Spike Protein (Neutralizing Antibodies) against the one previously supplied and used in Phase I and Phase II of the Sero-survey which is Qualitative / Semi quantitative in nature.

--PTO--

4. The Director of Public Health and Preventive Medicine has further stated that the timing of the Phase III sero-survey is very important one as it is being planned following the second COVID-19 wave in Tamil Nadu and also the intensified vaccination coverage in >18 years age group.

The Phase III of the Sero-survey will be intended to study

- i. Sero prevalence of COVID-19 in Tamil Nadu
- ii. Immune response to Natural Infection and Vaccination by a Quantitative IgG Assay using the current CLIA Platform.
- iii. Determine the Efficacy of Vaccination by measurable IgG level in the study population.

5. The Director of Public Health and Preventive Medicine has requested the Government to grant permission to conduct a COVID-19 Sero-survey Phase III in Tamil Nadu using a Quantitative Immuno Assay detecting IgG Antibodies against SARS CoV-2 Spike Protein.

6. The Government after careful examination, accord permission to the Director of Public Health and Preventive Medicine to conduct a COVID-19 Sero-Survey Phase – III in Tamil Nadu using a Quantitative Immuno Assay detecting IgG Antibodies against SARS CoV-2 Spike Protein.

(BY ORDER OF THE GOVERNOR)

J.RADHAKRISHNAN,
PRINCIPAL SECRETARY TO GOVERNMENT.

To

The Director of Public Health and Preventive Medicine, Chennai – 600 006.
The Managing Director,
Tamil Nadu Medical Services Corporation Limited, Chennai-600 008.

Copy to:

The Senior Personal Assistant to Hon'ble Minister (Medical and Family Welfare),
Secretariat, Chennai – 600 009.
✓ The Health and Family Welfare (Data Cell) Department, Chennai- 600 009.
Stock File / Spare Copy.

// FORWARDED BY ORDER //

B. Radhakrishnan
19/7/21
SECTION OFFICER

19/7/2021